Search results
Showing 1 to 15 of 33 results for erectile dysfunction
Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making
Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making
This indicator covers the percentage of male patients with diabetes who have a record of erectile dysfunction with a record of advice and assessment of contributory factors and treatment options in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM52
This indicator covers the percentage of male patients with diabetes with a record of being asked about erectile dysfunction in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM51
Evidence-based recommendations on angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunction in adults. This involves using a device to improve blood flow to the penis.
complications: diabetic kidney disease, eye disease, gastroparesis, erectile dysfunction Type 2 diabetes in adults: management Update in...
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
This quality standard covers managing prostate cancer in people referred to secondary care or having follow-up for prostate cancer in primary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS91Show all sections
Sections for QS91
- Quality statements
- Quality statement 1: Discussion with a named nurse specialist
- Quality statement 2: Treatment options
- Quality statement 3: Combination therapy
- Quality statement 4: Managing adverse effects of treatment
- Quality statement 5: Hormone-relapsed metastatic prostate cancer
- Update information
- About this quality standard
stenting to treat peripheral arterial disease causing refractory erectile dysfunction should provide clear details of patient selection....
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (MTG49)
Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.
View recommendations for MTG49Show all sections
This indicator covers the percentage of patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction, who are currently treated with a beta-blocker licensed for heart failure. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM173
Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG58)
Evidence-based recommendations on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia.
View recommendations for MTG58Show all sections